Data Transfer Restrictions: TTAM will not sell or transfer genetic data cannot be sold or transferred in connection with a subsequent bankruptcy or change of control unless the recipient is a ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...

"Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has ...

Regeneron Pharmaceuticals logged a 4.0% change during today's afternoon session, and is now trading at a price of $513.17 per ...

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

E.L.F. Beauty’s stock is up more than 34% in the last week. The positive performance, primarily driven by an over 23% surge on Thursday, comes after the company announced a $1 billion deal to acquire ...

According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, trading at an attractive P/E ratio of 14.36. For deeper insights into Regeneron’s valuation and ...